Nuveen’s Cidara Therapeutics CDTX Stock Holding History

Nuveen’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-43,127	Closed	-$9.53M	–	3240
2025 Q4	$9.53M	Sell	43,127 -2,757	-6%	-$446K	﹤0.01%	1584
2025 Q3	$4.39M	Buy	45,884 +8,056	+21%	+$514K	﹤0.01%	1967
2025 Q2	$1.84M	Buy	+37,828	New	+$909K	﹤0.01%	2341
2021 Q2	–	Sell	-9,876	Closed	-$526K	–	3388
2021 Q1	$526K	Buy	9,876 +3,113	+46%	+$154K	﹤0.01%	3087
2020 Q4	$270K	Buy	6,763 +66	+1%	+$3.28K	﹤0.01%	3157
2020 Q3	$382K	Sell	6,697 -1,448	-18%	-$102K	﹤0.01%	3025
2020 Q2	$602K	Buy	+8,145	New	+$528K	﹤0.01%	2828

Nuveen's CDTX Position: Q1 2026 in Review

Nuveen sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 43,127 shares — an estimated $9.53M sold.

Nuveen first reported a position in CDTX in Q2 2020 and held it in 7 quarters. The position peaked at $9.53M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Nuveen reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Nuveen sold 43,127 Cidara Therapeutics shares in Q1 2026, an estimated $9.53M.
Nuveen first reported a position in Cidara Therapeutics in Q2 2020 and held it in 7 quarters.
Nuveen's Cidara Therapeutics position peaked at $9.53M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.